By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Iris International said today it has completed its acquisition of AlliedPath for up to $6 million.

The deal was originally announced last week and includes $4.7 million in cash to AlliedPath and up to $1.3 million in an earn-out, subject to certain sales and earnings targets being met over the next three years.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.